are novel azalide derivatives of erythromycin that exhibit improved acid stability over erythromycin, azithromycin and clarithromycin. The half-life in aqueous solution at pH=2.1 of these compounds ranged from 0.3 hour for erythromycin to 16.2 hours for L-708,299. The rank order of half-life in acid solution from most to least stable was L-708,299 > L-701 ,677 > L-708,365 > azithromycin = clarithromycin > erythromycin. In a disseminated Streptococcus pyogenes mouse infection model, azithromycin and L-708,365 were slightly more efficacious than clarithromycin, L-701,677 and L-708,299; all 5 compounds being more active than erythromycin. In a Klebsiella pneumoniae pulmonary challenge mouse model, azithromycin, L-70 1 ,677, L-708,299 and L-708,365 were all equal in efficacy and at least four-fold more active than clarithromycin and erythromycin. Clarithromycin, L-708,365 and interestingly erythromycin, showed greater bacterial clearance than azitnromycin, L-701,677 and L-708,299 in a localized infection model that measured clearance of Staphylococcus aureus from mouse thigh tissues. Our results indicate that L-701,677, L-708,299 and L-708,365 exhibit improved acid stability and were at least equally efficacious as presently marketed macrolide/azalide antibiotics.
(Received for publication March 8, 1995) L-701,677, L-708,299 and L-708,365 are novel azalide derivatives of erythromycin that exhibit improved acid stability over erythromycin, azithromycin and clarithromycin. The half-life in aqueous solution at pH=2.1 of these compounds ranged from 0.3 hour for erythromycin to 16.2 hours for L-708,299. The rank order of half-life in acid solution from most to least stable was L-708,299 > L-701 ,677 > L-708,365 > azithromycin = clarithromycin > erythromycin. In a disseminated Streptococcus pyogenes mouse infection model, azithromycin and L-708,365 were slightly more efficacious than clarithromycin, L-701,677 and L-708,299; all 5 compounds being more active than erythromycin. In a Klebsiella pneumoniae pulmonary challenge mouse model, azithromycin, L-70 1 ,677, L-708,299 and L-708,365 were all equal in efficacy and at least four-fold more active than clarithromycin and erythromycin. Clarithromycin, L-708,365 and interestingly erythromycin, showed greater bacterial clearance than azitnromycin, L-701,677 and L-708,299 in a localized infection model that measured clearance of Staphylococcus aureus from mouse thigh tissues. Our results indicate that L-701,677, L-708,299 and L-708,365 exhibit improved acid stability and were at least equally efficacious as presently marketed macrolide/azalide antibiotics. Activity against intracellular pathogens has been attributed to the ability of erythromycin to penetrate and accumulate within humanphagocytic cells2).
Although erythromycin has been prescribed for over four decades, some problems with the drug remain.
Primarily, these are the marked variation in the bioavailability of oral preparations and side effects in the gastrointestinal tract. Variable absorption is presumably due to inactivation of the drug by the acid pH of the 
Acid Stability Studies
The half-life and percent residual activity of the macrolide compounds in acid were determined by diluting stock solutions of 1 mg/ml in 0.1 N HC1, pH = 2. 1, and incubating at room temperature for six hours. The pH of each compound was measured at t=0, 0.5, 1, 2, 3 and 6 hours. Samples from each timepoint were first neutralized by diluting 1 : 100 in Sorenson's phosphate buffer (pH= 8.0) and the concentration of compound remaining was determined by bioassay utilizing M. luteus ATCG 9341.
Streptococcus pyogenes Disseminated Model
A highly virulent S. pyogenes strain, MB2874, was utilized in this model. A 1 : 10,000 dilution of a seven hour culture prepared in Brain Heart broth supplemented with 10%horse serum and incubated at 35°C was used as the inoculum. CD-I mice were challenged intraperitoneally (I.P.) with approximately 6 x lO3 cells/0.5ml which was roughly 100 x the 14 day LD50. Compounds were tested at levels of 200, 50, 12.5 and 3.125mg/kg. and plate counts were determined on selective Mannitol salt agar. Colony counts from antibiotic-treated groups were compared to counts from sham-treated control groups.
Results
The comparative stability of the macrolide compounds in acid solution (pH=2.1) is shown in Fig. 2 In the S. pyogenes disseminated mouse model (Table   1) , at 7 days after challenge, azithromycin was two to % =Percent bioactivity remaining after 6 hours in acid solution. 
Discussion
Although erythromycin has been clinically useful in the treatment of skin, respiratory and genital tract infections, it has not been useful against infections caused by Gram-negative organisms such as Haemophilus influenzae. Also, due to poor absorption and gastro- 4-52.6) (17.4-52.6) >100 >100 >100 >100 1.95 7.07 (1.2-3.3) (3.6-13.9) ED50 = Effective dose in mg/kg that protected 50% of infected mice (10mice/group). Minimal inhibitory concentration determined by agar dilution method on Mueller Hinton agar. Mice were challenged with K. pneumoniae MB4005 at t=0 and treated P.O. or S.C. with compound0.5 hour after challenge, then 6 hours later, twice daily for three days (total of 6 doses). hours after challenge, then 6 hours later and continued twice daily for 3 days (total of 8 doses).
intestinal side effects after oral administration, its utility has been limited8). Recently marketed macrolides such as azithromycin, containing a methyl substituted nitrogen at position 9a of the lactone ring and clarithromycin with an O-methyl substitution at position 6 of the lactone ring have demonstrated improved gastric acid stability9'10) and exhibit distinct advantages over erythromycin. Both have longer half-lives, yield higher tissue levels and concentrations of both are increased in polymorphonuclear leukocytes and macrophagesll"17*. These properties along with the greater acid stability lead to a shorter course of therapy with improved patient compliance. These structural modifications also expand the spectrum of activity of these compounds over that of erythromycin. While comparable to erythromycin against most Gram-positive organisms, azithromycin and (T1/2 = 13.2 hours) exhibited stability more than twice that of azithromycin (T1/2=5.7 hours) and clarithromycin (T1/2 = 5.9 hours). The percent bioactivity demonstrated a positive correlation with the half life of these compounds. Pharmacokinetically, the serum parameters of these compounds were similar to those obtained for azithromycin, while tissue concentrations were lower (1~5 x) than those observed for azithromycin2 1}.
In the disseminated S. pyogenes mouse infection model azithromycin and L-708,365 were equal in efficacy at 7 days while azithromycin and clarithromycin were most active at 14 days. L-708,299 and L-701,677, with MICs<0.06/ig/ml, also exhibited good activity in this model. Erythromycin, which appeared to have very good potency in vitro (MIC value of 0.015//g/ml), was not efficaciousin this model even at doses as high as 200mg/kg. This inactivity could be attributable to the poor acid stability of erythromycin base at the pH of the stomach. Other formulations such as erythromycin stearate or enteric-coated tablets have been used to protect the antibiotic in the stomach8). Also, oral administration of one dose of erythromycin may have been insufficient to achieve peak and sustained serum levels required for efficacy in this model. three compoundswere found to be at least as potent as presently marketed macrolide compoundsin three mouse models of bacterial infection. Should their spectrum of activity be determined to be broader than the presently available agents, then further development and evaluation of these original compounds maybe warranted to determine their usefulness in treating a variety of skin, soft tissue and respiratory bacterial infections.
